Actinium Pharmaceuticals (ATNM) EBT Margin (2021 - 2026)

Actinium Pharmaceuticals (ATNM) posted quarterly EBT Margin of 7014.44% for Q3 2025, up 79.2% quarter-over-quarter from 33724.44% in Q3 2022.

Actinium Pharmaceuticals (ATNM) EBT Margin (2021 - 2026) Analysis & Trends

Actinium Pharmaceuticals (ATNM) has reported EBT Margin for 3 consecutive years, with 7014.44% the latest figure, recorded in Q3 2025.

In Q3 2025, EBT Margin changed N/A year-over-year to 7014.44%; the TTM figure through Dec 2025 stood at 26271.11% (changed N/A YoY), while the FY2025 annual figure was 36987.78%, changed N/A from the prior year.
EBT Margin grew to 7014.44% in Q3 2025 per ATNM's latest filing, from 33724.44% in the prior quarter.
Across five years, EBT Margin topped out at 559.36% in Q1 2022 and bottomed at 35404.35% in Q4 2021.
Historically, EBT Margin has averaged 12595.61% across 3 years, with a median of 5369.02% in 2021.
On a YoY basis, EBT Margin climbed as much as 31942 bps in 2022 and fell as far as 3000084 bps in 2022.
Actinium Pharmaceuticals' EBT Margin stood at 35404.35% in 2021, then grew by 5 bps to 33724.44% in 2022, then soared by 79 bps to 7014.44% in 2025.
Business Quant data shows ATNM's EBT Margin at 7014.44% in Q3 2025, 33724.44% in Q3 2022, and 17493.33% in Q2 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT Margin (Qtr)
1	Vertex Pharmaceuticals	140.14 Bn	132.29 Bn	2.84 Bn	41.75%
2	Regeneron Pharmaceuticals	87.02 Bn	79.03 Bn	3.93 Bn	35.61%
3	Argenx Se	65.30 Bn	60.12 Bn	1.37 Bn	35.71%
4	Moderna	60.84 Bn	55.70 Bn	52.00 Mn	-528.97%
5	BeOne Medicines	42.15 Bn	37.06 Bn	1.53 Bn	18.33%
6	Alnylam Pharmaceuticals	31.49 Bn	28.18 Bn	992.69 Mn	13.77%
7	BioNTech SE	28.78 Bn	10.38 Bn	668.28 Mn	-25.06%
8	Insmed	27.55 Bn	26.39 Bn	358.27 Mn	-2.67%
9	Royalty Pharma	27.14 Bn	26.31 Bn	-	12.09%
10	Actinium Pharmaceuticals	35.17 Mn	35.17 Mn	-	79.72%

Download Data